HYALRIPAYER-02 Chondropreparant, 5 ml with needle 1pc.

Chondroparative. The state of joint metabolism, viscoelastic and protective properties of synovial fluid are largely determined by the concentration in it of hyaluronic acid, a specific proteoglycan concentrated in cartilage, synovial membranes and other connective tissue structures of the body.

The action of GUALRIPAYER-02 gel material (chondropreparant) is based on the biological stimulation of natural metabolism processes, by means of which the physiological and rheological status of synovial fluid improves. GUALRIPAYER-02 gel material (chondropreparant) promotes deceleration of articular cartilage destruction in conjunction with the processes of restoration of synovial fluid homeostasis.

Gel material HYALRIPAIER-02 (chondropreparant) restores effective concentration of hyaluronic acid in the matrix, which leads to stimulation of fibroblasts and chondrocytes. Intermediate products of hyaluronic acid degradation have angiogenic, immunostimulatory and anti-inflammatory effects.

Gel material GIALRIPAYER-02 (chondropreparant) being a bioactive composition of modified hyaluronic acid with ascorbic acid and amino acids participating in the synthesis of collagen makes it possible to carry out directed delivery of active substances directly to the damaged connective tissue structures.

The structural modification of hyaluronic acid (polymer cross-linking) in the gel material HIALRIPAYER-02 (chondropreparant) provides prolonged reconstructive action on the cartilaginous, ligamentary and connective tissue structures of joints and extremities damaged due to injuries or degenerative-dystrophic processes.

In intra-articular injection the catabolic products of the gel material HIALRIPAYER-02 (chondropreparant), released amino acids, including the essential lysine, together with vitamin C create a physiologically favorable environment for strengthening the metabolic activity of cells and start the synthesis of the main components of the cartilage and connective tissue intercellular matrix.

Vitamin C in the material participates in the metabolic transformation of glycine, proline and lysine. Proline hydroxylation is necessary for stabilizing the triple helix of collagen and lysine hydroxylation is very important for the formation of covalent bonds between collagen molecules during the formation of collagen fibrils. This process is decisive for the stabilization of intercellular substance of all types of connective tissue.

Indications

Active ingredient

How to take, the dosage

1 treatment at an interval of 2 weeks,

4-6 treatments per course*

6-12 months**

*The dose, frequency of application and duration of the course is determined by the doctor individually.
** The interval between courses can be changed depending on the indications.

Interaction

The administration of Ripier-2 in combination with other drugs and products has not been investigated.

Special Instructions

General precautions for intra-articular injections should be observed.

Intra-articular gel material HIALRIPAYER-02 (chondropreparant) should not be injected if there are infected wounds, abrasions in the joint area, marked inflammation, significant intra-articular effusion, venous and lymphatic stasis on the side of the affected joint. Disinfectants containing quaternary ammonium salts must not be used for skin treatment prior to intraarticular injection. The material should be warmed to room temperature before injection.

The gel material HIALRIPAYER-02 (chondropreparant) must be gently injected into the joint cavity. After the injection of HIALRIPAIRE-02 gel (chondropreparant) it is recommended that the patient should be gentle and not put undue stress on the joint for several days.

Anesthetics and other pharmacological agents must not be administered into the affected joint cavity during the course of HIALRIPAIRE-02 (chondroparantine) gel injections.

Do not use the product with damaged packaging.

Contraindications

The following body conditions can be considered contraindications to the introduction of Hyalripire-2: disorders in the blood clotting system, acute respiratory diseases, the presence of malignant or benign tumors, pregnancy, lactation, chronic diseases of any system of the human body, in the acute stage, allergy to any of the components of this agent.

Side effects

During or after bioreparation with Hyalripire-2 the following side effects may occur: hyperemia in the injection area, swelling of subcutaneous tissue, itching, hematoma in the injection area, pain, changes in skin color.

Similarities